المؤلفون: Владимир Иванович Рудаев, Константин Николаевич Сиворонов, Елена Владимировна Рудаева

المصدر: Medicina v Kuzbasse, Vol 23, Iss 3, Pp 39-43 (2024)

مصطلحات موضوعية: синдром позиционного сдавления, рабдомиолиз, миоглобин, острое почечное повреждение, экстракорпоральная гемокоррекция, Medicine

وصف الملف: electronic resource

Relation: https://mednauki.ru/index.php/MK/article/view/1131; https://doaj.org/toc/1819-0901; https://doaj.org/toc/2588-0411

URL الوصول: https://doaj.org/article/466e9cb998f6488e9c8977f8e3e17153

المؤلفون: Ogarkova, D. V., Davydova, N. S., Sentsov, V. G., Огаркова, Д. В., Давыдова, Н. С., Сенцов, В. Г.

المصدر: Сборник статей

مصطلحات موضوعية: ALPHA-PYRROLIDINOPENTHIOPHENONE, RHABDOMYOLYSIS, ACUTE KIDNEY INJURY, RENAL REPLACEMENT THERAPY, АЛЬФА-ПИРРОЛИДИНОПЕНТИОФЕНОН, РАБДОМИОЛИЗ, ОСТРОЕ ПОВРЕЖДЕНИЯ ПОЧЕК, ЗАМЕСТИТЕЛЬНАЯ ПОЧЕЧНАЯ ТЕРАПИЯ

وصف الملف: application/pdf

Relation: Актуальные вопросы современной медицинской науки и здравоохранения : Сборник статей IX Международной научно-практической конференции молодых ученых и студентов, 17-18 апреля 2024 г. Т. 1.; Огаркова, Д. В. Случай рабдомиолиза при ингаляционном отравлении альфа – пирролидинопентиофеноном / Д. В. Огаркова, Н. С. Давыдова, В. Г. Сенцов. - Текст: электронный // Актуальные вопросы современной медицинской науки и здравоохранения : Сборник статей IX Международной научно-практической конференции молодых ученых и студентов, 17-18 апреля 2024 г. Т. 1. - Екатеринбург, 2024. – С. 180-184.; http://elib.usma.ru/handle/usma/21139

الاتاحة: http://elib.usma.ru/handle/usma/21139

المؤلفون: Bykova, E. S., Ovsova, O. V., Быкова, Е. С., Овсова, О. В.

المصدر: Сборник статей

مصطلحات موضوعية: MALIGNANT HYPERTHERMIA, RHABDOMYOLYSIS, ANAESTHETIC, GENE RYR1, ЗЛОКАЧЕСТВЕННАЯ ГИПЕРТЕРМИЯ, РАБДОМИОЛИЗ, АНЕСТЕТИКИ, ГЕН RYR 1

وصف الملف: application/pdf

Relation: Актуальные вопросы современной медицинской науки и здравоохранения: сборник статей VIII Международной научно-практической конференции молодых учёных и студентов, Екатеринбург, 19-20 апреля 2023 г.; Быкова, Е. С. Злокачественная гипертемия: клинический случай / Е. С. Быкова, О. В. Овсова. - Текст электронный. // Актуальные вопросы современной медицинской науки и здравоохранения: сборник статей VIII Международной научно-практической конференции молодых учёных и студентов, Екатеринбург, 19-20 апреля 2023 г. – Екатеринбург : УГМУ, 2023. – C. 2081-2086.; http://elib.usma.ru/handle/usma/14292

الاتاحة: http://elib.usma.ru/handle/usma/14292

المؤلفون: D. A. Sychev, T. M. Ostroumova, O. D. Ostroumova, A. I. Kochetkov, S. V. Batyukina, E. V. Mironova, Д. А. Сычев, Т. М. Остроумова, О. Д. Остроумова, А. И. Кочетков, С. В. Батюкина, Е. В. Миронова

المساهمون: The study was performed without external funding, Работа выполнена без спонсорской поддержки

المصدر: Safety and Risk of Pharmacotherapy; Том 11, № 3 (2023); 252-270 ; Безопасность и риск фармакотерапии; Том 11, № 3 (2023); 252-270 ; 2619-1164 ; 2312-7821

مصطلحات موضوعية: статин-индуцированная некротизирующая аутоиммунная миопатия, adverse drug reactions, lipid-lowering medicinal products, statins, myopathy, myalgia, myositis, rhabdomyolysis, statin-induced necrotising autoimmune myopathy, SINAM, нежелательные реакции, гиполипидемические средства, статины, миопатия, миалгия, миозит, рабдомиолиз

وصف الملف: application/pdf

Relation: https://www.risksafety.ru/jour/article/view/391/877; https://www.risksafety.ru/jour/article/downloadSuppFile/391/419; Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol. 2002;40(3):567–72. https://doi.org/10.1016/s0735-1097(02)02030-2; Tisdale JE, Miller DA. Drug induced diseases: prevention, detection, and management. 3rd ed. Bethesda, Md.: American Society of Health-System Pharmacists; 2018.; Jain КК. Drug-induced neurological disorders. 4th ed. Springer; 2021. https://doi.org/10.1007/978-3-030-73503-6; Gupta A, Gupta Y. Glucocorticoid-induced myopathy: pathophysiology, diagnosis, and treatment. Indian J Endocrinol Metab. 2013;17(5):913–6. https://doi.org/10.4103/2230-8210.117215; Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003;289(13):1681–90. https://doi.org/10.1001/jama.289.13.1681; Fernandez G, Spatz ES, Jablecki C, Phillips PS. Statin myopathy: a common dilemma not reflected in clinical trials. Cleve Clin J Med. 2011;78(6):393–403. https://doi.org/10.3949/ccjm.78a.10073; Напалков ДА. Безопасность статинов: что нужно знать практикующему врачу? Рациональная фармакотерапия в кардиологии. 2014;10(3):334–8. https://doi.org/10.20996/1819-6446-2014-10-3-334-338; Guyton JR, Bays HE, Grundy SM, Jacobson TA, The National Lipid Association Statin Intolerance Panel. An assessment by the Statin Intolerance Panel: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S72–81. https://doi.org/10.1016/j.jacl.2014.03.002; Дядык АИ, Куглер ТЕ, Зборовский СР, Сулиман ЮВ. Статин-ассоциированные мышечные симптомы: эпидемиология, факторы риска, механизмы развития и лечебная тактика. Кардиология. 2019;59(5S):4–12. https://doi.org/10.18087/cardio.2522; Ballantyne CM, Corsini A, Davidson MH, Holdaas H, Jacobson TA, Leitersdorf E, et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med. 2003;163(5):553–64. https://doi.org/10.1001/archinte.163.5.553; Furberg CD, Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med. 2001;2(5):205–7. https://doi.org/10.1186/cvm-2-5-205; Kashani A, Phillips CO, Foody JM, Wang Y, Mangalmurti S, Ko DT, Krumholz HM. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation. 2006;114(25):2788–97. https://doi.org/10.1161/CIRCULATIONAHA.106.624890; Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;36(17):1012–22. https://doi.org/10.1093/eurheartj/ehv043; Janssen L, Allard NAE, Saris CGJ, Keijer J, Hopman MTE, Timmers S. Muscle toxicity of drugs: when drugs turn physiology into pathophysiology. Physiol Rev. 2020;100(2):633–72. https://doi.org/10.1152/physrev.00002.2019; Hansen KE, Hildebrand JP, Ferguson EE, Stein JH. Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med. 2005;165(22):2671–6. https://doi.org/10.1001/archinte.165.22.2671; Сумароков АБ. Аутоиммунная некротизирующая статин-индуцированная миопатия. Атеросклероз и дислипидемии. 2022;2(47):5–9. https://doi.org/10.34687/2219-8202.JAD.2022.02.0001; Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(10059): 2532–61. https://doi.org/10.1016/S0140-6736(16)31357-5; Mammen AL, Chung T, Christopher-Stine L, Rosen P, Rosen A, Doering KR, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 2011;63(3):713–21. https://doi.org/10.1002/art.30156; Mohassel P, Mammen AL. Anti-HMGCR myopathy. J Neuromuscul Dis. 2018;5(1):11–20. https://doi.org/10.3233/JND-170282; Pinal-Fernandez I, Casal-Dominguez M, Mammen AL. Immune-mediated necrotizing myopathy. Curr Rheumatol Rep. 2018;20(4):21. https://doi.org/10.1007/s11926-018-0732-6; Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med. 2002;346(7):539–40. https://doi.org/10.1056/NEJM200202143460721; Cziraky MJ, Willey VJ, McKenney JM, Kamat SA, Fisher MD, Guyton JR, et al. Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting. J Clin Lipidol. 2013;7(2):102–8. https://doi.org/10.1016/j.jacl.2012.06.006; Cziraky MJ, Willey VJ, McKenney JM, Kamat SA, Fisher MD, Guyton JR, et al. Statin safety: an assessment using an administrative claims database. Am J Cardiol. 2006;97(8A):61C–68C. https://doi.org/10.1016/j.amjcard.2005.12.011; Mohassel P, Mammen AL. Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies. Muscle Nerve. 2013;48(4):477–83. https://doi.org/10.1002/mus.23854; Taylor BA, Thompson PD. Muscle-related side-effects of statins: from mechanisms to evidence-based solutions. Curr Opin Lipidol. 2015;26(3):221–7. https://doi.org/10.1097/MOL.0000000000000174; Finegold JA, Manisty CH, Goldacre B, Barron AJ, Francis DP. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice. Eur J Prev Cardiol. 2014;21(4):464–74. https://doi.org/10.1177/2047487314525531; Ganga HV, Slim HB, Thompson PD. A systematic review of statin-induced muscle problems in clinical trials. Am Heart J. 2014;168(1):6–15. https://doi.org/10.1016/j.ahj.2014.03.019; Gupta A, Thompson D, Whitehouse A, Collier T, Dahlof B, Poulter N, et al. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet. 2017;389(10088):2473–81. https://doi.org/10.1016/S0140-6736(17)31075-9; Liao JK. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. Curr Atheroscler Rep. 2009;11(4):243–4. https://doi.org/10.1007/s11883-009-0037-3; MRC/BHF Heart Protection Study Collaborative Group; Armitage J, Bowman L, Collins R, Parish S, Tobert J. Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people. BMC Clin Pharmacol. 2009;9:6. https://doi.org/10.1186/1472-6904-9-6; Keech A, Collins R, MacMahon S, Armitage J, Lawson A, Wallendszus K, et al. Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study. Eur Heart J. 1994;15(2):255–69. https://doi.org/10.1093/oxfordjournals.eurheartj.a060485; Cai T, Abel L, Langford O, Monaghan G, Aronson JK, Stevens RJ, et al. Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses. BMJ. 2021;374:n1537. https://doi.org/10.1136/bmj.n1537; Parker BA, Capizzi JA, Grimaldi AS, Clarkson PM, Cole SM, Keadle J, et al. Effect of statins on skeletal muscle function. Circulation. 2013;127(1):96–103. https://doi.org/10.1161/CIRCULATIONAHA.112.136101; Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients — the PRIMO study. Cardiovasc Drugs Ther. 2005;19(6):403–14. https://doi.org/10.1007/s10557-005-5686-z; Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group; Armitage J, Bowman L, Wallendszus K, Bulbulia R, Rahimi K, et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet. 2010;376(9753):1658–69. https://doi.org/10.1016/S0140-6736(10)60310-8; Naci H, Brugts J, Ades T. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials. Circ Cardiovasc Qual Outcomes. 2013;6(4):390–9. https://doi.org/10.1161/CIRCOUTCOMES.111.000071; Yebyo HG, Aschmann HE, Kaufmann M, Puhan MA. Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants. Am Heart J. 2019;210:18–28. https://doi.org/10.1016/j.ahj.2018.12.007; Mach F, Ray KK, Wiklund O, Corsini A, Catapano AL, Bruckert E, et al. Adverse effects of statin therapy: perception vs. the evidence — focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. Eur Heart J. 2018;39(27):2526–39. https://doi.org/10.1093/eurheartj/ehy182; Nielsen SF, Nordestgaard BG. Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study. Eur Heart J. 2016;37(11):908–16. https://doi.org/10.1093/eurheartj/ehv641; Serban MC, Colantonio LD, Manthripragada AD, Monda KL, Bittner VA, Banach M, et al. Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction. J Am Coll Cardiol. 2017;69(11):1386–95. https://doi.org/10.1016/j.jacc.2016.12.036; Matthews A, Herrett E, Gasparrini А, Van Staa Т, Goldacre В, Smeeth L, et al. Impact of statin related media coverage on use of statins: interrupted time series analysis with UK primary care data. BMJ. 2016;353:i3283. https://doi.org/10.1136/bmj.i3283; Tobert JA, Newman CB. The nocebo effect in the context of statin intolerance. J Clin Lipidol. 2016;10(4):739–47. https://doi.org/10.1016/j.jacl.2016.05.002; Vinci P, Panizon E, Tosoni LM, Cerrato C, Pellicori F, Mearelli F, et al. Statin-associated myopathy: emphasis on mechanisms and targeted therapy. Int J Mol Sci. 2021;22(21):11687. https://doi.org/10.3390/ijms222111687; Arouche-Delaperche L, Allenbach Y, Amelin D, Preusse C, Mouly V, Mauhin W. Pathogenic role of anti-signal recognition protein and anti-3-hydroxy-3-methylglutaryl-coa reductase anti-bodies in necrotizing myopathies: Myofiber atrophy and impairment of muscle regeneration in necrotizing autoimmune myopathies. Ann Neurol. 2017;81(4):538–48. https://doi.org/10.1002/ana.24902; Kaufmann P, Török M, Zahno A, Waldhauser KM, Brecht K, Krähenbühl S. Toxicity of statins on rat skeletal muscle mitochondria. Cell Mol Life Sci. 2006;63(19–20):2415–25. https://doi.org/10.1007/s00018-006-6235-z; Wiel C, Lallet-Daher H, Gitenay D, Gras B, Le Calvé B, Augert A, et al. Endoplasmic reticulum calcium release through ITPR2 channels leads to mitochondrial calcium accumulation and senescence. Nat Commun. 2014;5:3792. https://doi.org/10.1038/ncomms4792; Ghatak A, Faheem O, Thompson PD. The genetics of statin-induced myopathy. Atherosclerosis. 2010;210(2):337–43. https://doi.org/10.1016/j.atherosclerosis.2009.11.033; Marez D, Legrand M, Sabbagh N, Lo Guidice JM, Spire C, Lafitte JJ, et al. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics. 1997;7(3):193–202. https://doi.org/10.1097/00008571-199706000-00004; Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjöqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA. 1993;90(24):11825–9. https://doi.org/10.1073/pnas.90.24.11825; Gluba-Brzozka A, Franczyk B, Toth PP, Rysz J, Banach M. Molecular mechanisms of statin intolerance. Arch Med Sci. 2016;12(3):645–58. https://doi.org/10.5114/aoms.2016.59938; Wilke RA, Moore JH, Burmester JK. Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage. Pharmacogenet Genomics. 2005;15(6):415–21. https://doi.org/10.1097/01213011-200506000-00007; Dobkin BH. Underappreciated statin-induced myopathic weakness causes disability. Neurorehabil Neural Repair. 2005;19(3):259–63. https://doi.org/10.1177/1545968305277167; Reiner Z. Resistance and intolerance to statins. Nutr Metab Cardiovasc Dis. 2014;24(10):1057–66. https://doi.org/10.1016/j.numecd.2014.05.009; Sirtori CR, Mombelli G, Triolo M, Laaksonen R. Clinical response to statins: mechanism(s) of variable activity and adverse effects. Ann Med. 2012;44(5):419–32. https://doi.org/10.3109/07853890.2011.582135; Duman I. Role of pharmacogenetics on response to statins: A genotype-based approach to statin therapy outcome. J Cardiol Therapy. 2014;1(6):111–20.; Bieber LL. Carnitine. Annu Rev Biochem. 1988;57:261–83. https://doi.org/10.1146/annurev.bi.57.070188.001401; Sigauke E, Rakheja D, Kitson K, Bennett MJ. Carnitine palmitoyltransferase II deficiency: a clinical, biochemical, and molecular review. Lab Invest. 2003;83(11):1543–54. https://doi.org/10.1097/01.lab.0000098428.51765.83; Flint OP, Masters BA, Gregg RE, Durham SK. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. Toxicol Appl Pharmacol. 1997;145(1):91–8. https://doi.org/10.1006/taap.1997.8131; Vladutiu GD, Simmons Z, Isackson PJ, Tarnopolsky M, Peltier WL, Barboi AC, et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve. 2006;34(2):153–62. https://doi.org/10.1002/mus.20567; Tay SK, Dimauro S, Pang AY, Lai PS, Yap HK. Myotoxicity of lipid-lowering agents in a teenager with MELAS mutation. Pediatr Neurol. 2008;39(6):426–8. https://doi.org/10.1016/j.pediatrneurol.2008.09.002; Tsivgoulis G, Spengos K, Karandreas N, Panas M, Kla di A, Manta P. Presymptomatic neuromuscular disorders disclosed following statin treatment. Arch Intern Med. 2006;166(14):1519–24. https://doi.org/10.1001/archinte.166.14.1519; Chariot P, Abadia R, Agnus D, Danan C, Charpentier C, Gherardi RK. Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome. Am J Med. 1993;94(1):109–10. https://doi.org/10.1016/0002-9343(93)90129-d; Hur J, Liu Z, Tong W, Laaksonen R, Bai JP. Drug-induced rhabdomyolysis: from systems pharmacology analysis to biochemical flux. Chem Res Toxicol. 2014;27(3):421–32. https://doi.org/10.1021/tx400409c; Skottheim IB, Gedde-Dahl A, Hejazifar S, Hoel K, Asberg A. Statin induced myotoxicity: the lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro. Eur J Pharm Sci. 2008;33(4–5):317–25. https://doi.org/10.1016/j.ejps.2007.12.009; Schirris TJ, Ritschel T, Bilos A, Smeitink JA, Russel FG. Statin lactonization by uridine 5’-diphospho-glucuronosyltransferases (UGTs). Mol Pharm. 2015;12(11):4048–55. https://doi.org/10.1021/acs.molpharmaceut.5b00474; Wagner BK, Gilbert TJ, Hanai J, Imamura S, Bodycombe NE, Bon RS, et al. A small-molecule screening strategy to identify suppressors of statin myopathy. ACS Chem Biol. 2011;6(9):900–4. https://doi.org/10.1021/cb200206w; Wagner BK, Kitami T, Gilbert TJ, Peck D, Ramanathan A, Schreiber SL, et al. Large-scale chemical dissection of mitochondrial function. Nat Biotechnol. 2008;26(3):343–51. https://doi.org/10.1038/nbt1387; Kavalipati N, Shah J, Ramakrishan A, Vasnawala H. Pleiotropic effects of statins. Indian J Endocrinol Metab. 2015;19(5):554–62. https://doi.org/10.4103/2230-8210.163106; Phillips PS, Haas RH, Bannykh S, Hathaway S, Gray NL, Kimura BJ, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med. 2002;137(7):581–5. https://doi.org/10.7326/0003-4819-137-7-200210010-00009; Guijarro C, Blanco-Colio LM, Ortego M, Alonso C, Ortiz A, Plaza JJ, et al. 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res. 1998;83(5):490–500. https://doi.org/10.1161/01.res.83.5.490; Hernández-Camacho JD, Bernier M, López-Lluch G, Navas P. Coenzyme Q10 supplementation in aging and disease. Front Physiol. 2018;9:44. https://doi.org/10.3389/fphys.2018.00044; Eriksson EK, Agmo Hernández V, Edwards K. Effect of ubiquinone-10 on the stability of biomimetic membranes of relevance for the inner mitochondrial membrane. Biochim Biophys Acta Biomembr. 2018;1860(5):1205–15. https://doi.org/10.1016/j.bbamem.2018.02.015; Xu Z, Huo J, Ding X, Yang M, Li L, Dai J, et al. Coenzyme Q10 improves lipid metabolism and ameliorates obesity by regulating CaMKII-mediated PDE4 inhibition. Sci Rep. 2017;7(1):8253. https://doi.org/10.1038/s41598-017-08899-7; Qu H, Guo M, Chai H, Wang WT, Gao ZY, Shi DZ. Effects of coenzyme Q10 on statin-induced myopathy: an updated meta-analysis of randomized controlled trials. J Am Heart Assoc. 2018;7(19):e009835. https://doi.org/10.1161/JAHA.118.009835; Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol. 2007;49(23):2231–7. https://doi.org/10.1016/j.jacc.2007.02.049; Vaklavas C, Chatzizisis YS, Ziakas A, Zamboulis C, Giannoglou GD. Molecular basis of statin-associated myopathy. Atherosclerosis. 2009;202(1):18–28. https://doi.org/10.1016/j.atherosclerosis.2008.05.021; Hattori T, Saito K, Takemura M, Ito H, Ohta H, Wada H, et al. Statin-induced Ca(2+) release was increased in B lymphocytes in patients who showed elevated serum creatine kinase during statin treatment. J Atheroscler Thromb. 2009;16(6):870–7. https://doi.org/10.5551/jat.2048; Nakahara K, Yada T, Kuriyama M, Osame M. Cytosolic Ca2+ increase and cell damage in L6 rat myoblasts by HMGCoA reductase inhibitors. Biochem Biophys Res Commun. 1994;202(3):1579–85. https://doi.org/10.1006/bbrc.1994.2112; Sirvent P, Mercier J, Vassort G, Lacampagne A. Simvastatin triggers mitochondria-induced Ca2+ signaling alteration in skeletal muscle. Biochem Biophys Res Commun. 2005;329(3):1067–75. https://doi.org/10.1016/j.bbrc.2005.02.070; Roten L, Schoenenberger RA, Krähenbühl S, Schlienger RG. Rhabdomyolysis in association with simvastatin and amiodarone. Ann Pharmacother. 2004;38(6):978–81. https://doi.org/10.1345/aph.1D498; Schirris TJ, Renkema GH, Ritschel T, Voermans NC, Bilos A, van Engelen BG, et al. Statin-induced myopathy is associated with mitochondrial complex III inhibition. Cell Metab. 2015;22(3):399–407. https://doi.org/10.1016/j.cmet.2015.08.002; Banach M, Serban C, Sahebkar A, Ursoniu S, Rysz J, Muntner P, et al. Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clin Proc. 2015;90(1):24–34. https://doi.org/10.1016/j.mayocp.2014.08.021; Moßhammer D, Schaeffeler E, Schwab M, Mörike K. Mechanisms and assessment of statin-related muscular adverse effects. Br J Clin Pharmacol. 2014;78(3):454–66. https://doi.org/10.1111/bcp.12360; Itagaki M, Takaguri A, Kano S, Kaneta S, Ichihara K, Satoh K. Possible mechanisms underlying statin-induced skeletal muscle toxicity in L6 fibroblasts and in rats. J Pharmacol Sci. 2009;109(1):94–101. https://doi.org/10.1254/jphs.08238fp; Cao P, Hanai J, Tanksale P, Imamura S, Sukhatme VP, Lecker SH. Statin-induced muscle damage and atrogin-1 induction is the result of a geranylgeranylation defect. FASEB J. 2009;23(9):2844–54. https://doi.org/10.1096/fj.08-128843; Draeger A, Monastyrskaya K, Mohaupt M, Hoppeler H, Savolainen H, Allemann C, Babiychuk EB. Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia. J Pathol. 2006;210(1):94–102. https://doi.org/10.1002/path.2018; Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve FJ, et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol. 2015;9(6):758–69. https://doi.org/10.1016/j.jacl.2015.08.006; Koren MJ, Sabatine MS, Giugliano RP, Langslet G, Wiviott SD, Ruzza A, et al. Long-term efficacy and safety of evolocumab in patients with hypercholesterolemia. J Am Coll Cardiol. 2019;74(17):2132–46. https://doi.org/10.1016/j.jacc.2019.08.1024; Buettner C, Lecker SH. Molecular basis for statin-induced muscle toxicity: implications and possibilities. Pharmacogenomics. 2008;9(8):1133–42. https://doi.org/10.2217/14622416.9.8.1133; Lotteau S, Ivarsson N, Yang Z, Restagno D, Colyer J, Hopkins P, et al. A mechanism for statin-induced susceptibility to myopathy. JACC Basic Transl Sci. 2019;4(4):509–23. https://doi.org/10.1016/j.jacbts.2019.03.012; Marciante KD, Durda JP, Heckbert SR, Lumley T, Rice K, McKnight B, et al. Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics. 2011;21(5):280–8. https://doi.org/10.1097/FPC.0b013e328343dd7d; Elam MB, Majumdar G, Mozhui K, Gerling IC, Vera SR, Fish-Trotter H, et al. Patients experiencing statin-induced myalgia exhibit a unique program of skeletal muscle gene expression following statin re-challenge. PLoS One. 2017;12(8):e0181308. https://doi.org/10.1371/journal.pone.0181308; Mangravite LM, Engelhardt BE, Medina MW, Smith JD, Brown CD, Chasman DI, et al. A statin-dependent QTL for GATM expression is associated with statin-induced myopathy. Nature. 2013;502(7471):377–80. https://doi.org/10.1038/nature12508; Luzum JA, Kitzmiller JP, Isackson PJ, Ma C, Medina MW, Dauki AM, et al. GATM polymorphism associated with the risk for statin-induced myopathy does not replicate in case-control analysis of 715 dyslipidemic individuals. Cell Metab. 2015;21(4):622–7. https://doi.org/10.1016/j.cmet.2015.03.003; Carr DF, Alfirevic A, Johnson R, Chinoy H, van Staa T, Pirmohamed M. GATM gene variants and statin myopathy risk. Nature. 2014;513(7518):E1. https://doi.org/10.1038/nature13628; Floyd JS, Bis JC, Brody JA, Heckbert SR, Rice K, Psaty BM. GATM locus does not replicate in rhabdomyolysis study. Nature. 2014;513(7518):E1–3. https://doi.org/10.1038/nature13629; Carr DF, Francis B, Jorgensen AL, Zhang E, Chinoy H, Heckbert SR, et al. Genomewide Association Study of statin-induced myopathy in patients recruited using the UK Clinical Practice Research Datalink. Clin Pharmacol Ther. 2019;106(6):1353–61. https://doi.org/10.1002/cpt.1557; Floyd JS, Bloch KM, Brody JA, Maroteau C, Siddiqui MK, Gregory R, et al. Pharmacogenomics of statin-related myopathy: Meta-analysis of rare variants from whole-exome sequencing. PLoS One. 2019;14(6):e0218115. https://doi.org/10.1371/journal.pone.0218115; Dubé MP, Zetler R, Barhdadi A, Brown AM, Mongrain I, Normand V, et al. CKM and LILRB5 are associated with serum levels of creatine kinase. Circ Cardiovasc Genet. 2014;7(6):880–6. https://doi.org/10.1161/CIRCGENETICS.113.000395; Kuswanto W, Burzyn D, Panduro M, Wang KK, Jang YC, Wagers AJ, et al. Poor repair of skeletal muscle in aging mice reflects a defect in local, interleukin-33-dependent accumulation of regulatory T cells. Immunity. 2016;44(2):355–67. https://doi.org/10.1016/j.immuni.2016.01.009; Grable-Esposito P, Katzberg HD, Greenberg SA, Srinivasan J, Katz J, Amato AA. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve. 2010;41(2):185–90. https://doi.org/10.1002/mus.21486; Needham M, Fabian V, Knezevic W, Panegyres P, Zilko P, Mastaglia FL. Progressive myopathy with up-regulation of MHC-I associated with statin therapy. Neuromuscul Disord. 2007;17(2):194–200. https://doi.org/10.1016/j.nmd.2006.10.007; Christopher-Stine L, Casciola-Rosen LA, Hong G, Chung T, Corse AM, Mammen AL. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum. 2010;62(9):2757–66. https://doi.org/10.1002/art.27572; Mammen AL, Gaudet D, Brisson D, Christopher-Stine L, Lloyd TE, Leffell MS, et al. Increased frequency of DRB1*11:01 in anti-hydroxymethylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Care Res (Hoboken). 2012;64(8):1233–7. https://doi.org/10.1002/acr.21671; Werner JL, Christopher-Stine L, Ghazarian SR, Pak KS, Kus JE, Daya NR, et al. Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Rheum. 2012;64(12):4087–93. https://doi.org/10.1002/art.34673; Parker BA, Augeri AL, Capizzi JA, Ballard KD, Troyanos C, Baggish AL, et al. Effect of statins on creatine kinase levels before and after a marathon run. Am J Cardiol. 2012;109(2):282–7. https://doi.org/10.1016/j.amjcard.2011.08.045; Noyes AM, Thompson PD. The effects of statins on exercise and physical activity. J Clin Lipidol. 2017;11(5):1134–44. https://doi.org/10.1016/j.jacl.2017.07.003; Chalchat E, Charlot K, Garcia-Vicencio S, Hertert P, Baugé S, Bourdon S, et al. Circulating microRNAs after a 24-h ultramarathon run in relation to muscle damage markers in elite athletes. Scand J Med Sci Sports. 2021;31(9):1782–95. https://doi.org/10.1111/sms.14000; Min PK, Park J, Isaacs S, Taylor BA, Thompson PD, Troyanos C, et al. Influence of statins on distinct circulating microRNAs during prolonged aerobic exercise. J Appl Physiol (1985). 2016;120(6):711–20. https://doi.org/10.1152/japplphysiol.00654.2015; Lowe K, Kubra KT, He ZY, Carey K. Vitamin D supplementation to treat statin-associated muscle symptoms: a review. Sr Care Pharm. 2019;34(4):253–7. https://doi.org/10.4140/TCP.n.2019.253; Gupta A, Thompson PD. The relationship of vitamin D deficiency to statin myopathy. Atherosclerosis. 2011;215(1):23–9. https://doi.org/10.1016/j.atherosclerosis.2010.11.039; Bikle DD. Vitamin D metabolism, mechanism of action, and clinical applications. Chem Biol. 2014;21(3):319–29. https://doi.org/10.1016/j.chembiol.2013.12.016; Mazidi M, Rezaie P, Vatanparast H, Kengne AP. Effect of statins on serum vitamin D concentrations: a systematic review and meta-analysis. Eur J Clin Invest. 2017;47(1):93– 101. https://doi.org/10.1111/eci.12698; Schwartz JB. Effects of vitamin D supplementation in atorvastatin-treated patients: a new drug interaction with an unexpected consequence. Clin Pharmacol Ther. 2009;85(2):198–203. https://doi.org/10.1038/clpt.2008.165; Michalska-Kasiczak M, Sahebkar A, Mikhailidis DP, Rysz J, Muntner P, Toth PP, et al. Analysis of vitamin D levels in patients with and without statin-associated myalgia — a systematic review and meta-analysis of 7 studies with 2420 patients. Int J Cardiol. 2015;178:111–6. https://doi.org/10.1016/j.ijcard.2014.10.118; Ahmed W, Khan N, Glueck CJ, Pandey S, Wang P, Goldenberg N, et al. Low serum 25 (OH) vitamin D levels (; Glueck CJ, Lee K, Prince M, Milgrom A, Makadia F, Wang P. Low serum vitamin D, statin associated muscle symptoms, vitamin D supplementation. Atherosclerosis. 2017;256:125–7. https://doi.org/10.1016/j.atherosclerosis.2016.11.027; Jetty V, Glueck CJ, Wang P, Shah P, Prince M, Lee K, et al. Safety of 50,000–100,000 units of vitamin D3/week in vitamin D-deficient, hypercholesterolemic patients with reversible statin intolerance. N Am J Med Sci. 2016;8(3):156–62. https://doi.org/10.4103/1947-2714.179133; Kang JH, Nguyen QN, Mutka J, Le QA. Rechallenging statin therapy in veterans with statin-induced myopathy post vitamin D replenishment. J Pharm Pract. 2017;30(5):521–7. https://doi.org/10.1177/0897190016674407; Wadhera RK, Steen DL, Khan I, Giugliano RP, Foody JM. A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality. J Clin Lipidol. 2016;10(3):472–89. https://doi.org/10.1016/j.jacl.2015.11.010; Safitri N, Alaina MF, Pitaloka DAE, Abdulah R. A narrative review of statin-induced rhabdomyolysis: molecular mechanism, risk factors, and management. Drug Healthc Patient Saf. 2021;13:211–9. https://doi.org/10.2147/DHPS.S333738; Di Stasi SL, MacLeod TD, Winters JD, Binder-Macleod SA. Effects of statins on skeletal muscle: a perspective for physical therapists. Phys Ther. 2010;90(10):1530–42. https://doi.org/10.2522/ptj.20090251; Tanaka S, Sakamoto K, Yamamoto M, Mizuno A, Ono T, Waguri S, et al. Mechanism of statin-induced contractile dysfunction in rat cultured skeletal myofibers. J Pharmacol Sci. 2010;114(4):454–63. https://doi.org/10.1254/jphs.10229fp; Sakamoto K, Honda T, Yokoya S, Waguri S, Kimura J. Rabsmall GTPases are involved in fluvastatin and pravastatin-induced vacuolation in rat skeletal myofibers. FASEB J. 2007;21(14):4087–94. https://doi.org/10.1096/fj.07-8713com; Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther. 2006;112(1):71–105. https://doi.org/10.1016/j.pharmthera.2006.03.003; Knauer MJ, Urquhart BL, Meyer zu Schwabedissen HE, Schwarz UI, Lemke CJ, Leake BF, et al. Human skeletal muscle drug transporters determine local exposure and toxicity of statins. Circ Res. 2010;106(2):297–306. https://doi.org/10.1161/CIRCRESAHA.109.203596; Silva M, Matthews ML, Jarvis C, Nolan NM, Belliveau P, Malloy M, Gandhi P. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin Ther. 2007;29(2):253–60. https://doi.org/10.1016/j.clinthera.2007.02.008; Muñoz-Blanco A, Gómez-Huelgas R, Gómez-Cerezo JF. Statin-associated muscle symptoms: myth or reality? Rev Clin Esp (Barc). 2022;222(10):602–11. https://doi.org/10.1016/j.rceng.2022.03.006; Сычев ДА, Остроумова ОД, Переверзев АП, ред. Лекарственнo-индуцированные заболевания. Т. I. М.: Прометей; 2022.; Canestaro WJ, Austin MA, Thummel KE. Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review. Genet Med. 2014;16(11):810–9. https://doi.org/10.1038/gim.2014.41; SEARCH Collaborative Group; Link E, Parish S, Armitage J, Bowman L, Heath S, et al. SLCO1B1 variants and statin-induced myopathy — a genomewide study. N Engl J Med. 2008;359(8):789–99. https://doi.org/10.1056/NEJMoa0801936; Danik JS, Chasman DI, MacFadyen JG, Nyberg F, Barratt BJ, Ridker PM. Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy. Am Heart J. 2013;165(6):1008–14. https://doi.org/10.1016/j.ahj.2013.01.025; Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother. 2002;36(2):288–95. https://doi.org/10.1345/aph.1A289; Newman CB, Preiss D, Tobert JA, Jacobson TA, Page RL 2nd, Goldstein LB, et al. Statin safety and associated adverse events: a scientific statement from the american heart association. Arterioscler Thromb Vasc Biol. 2019;39(2):e38–e81. https://doi.org/10.1161/ATV.0000000000000073; LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425–35. https://doi.org/10.1056/NEJMoa050461; Schech S, Graham D, Staffa J, Andrade SE, La Grenade L, Burgess M, et al. Risk factors for statin-associated rhabdomyolysis. Pharmacoepidemiol Drug Saf. 2007;16(3):352–8. https://doi.org/10.1002/pds.1287; Кухарчук ВВ, Ежов МВ, Сергиенко ИВ, Арабидзе ГГ, Бубнова МГ, Балахонова ТВ и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VII пересмотр. Атеросклероз и дислипидемии. 2020;(1):7–40. https://doi.org/10.34687/2219-8202.JAD.2020.01.0002; Rosenson RS, Miller K, Bayliss M, Sanchez RJ, Baccara-Dinet MT, Chibedi-De-Roche D, et al. The Statin-associated muscle symptom clinical index (SAMS-CI): revision for clinical use, content validation, and inter-rater reliability. Cardiovasc Drugs Ther. 2017;31(2):179–86. https://doi.org/10.1007/s10557-017-6723-4; Lamperti C, Naini AB, Lucchini V, Prelle A, Bresolin N, Moggio M, et al. Muscle coenzyme Q10 level in statin-related myopathy. Arch Neurol. 2005;62(11):1709–12. https://doi.org/10.1001/archneur.62.11.1709; Gambelli S, Dotti MT, Malandrini A, Mondelli M, Stromillo ML, Gaudiano C, et al. Mitochondrial alterations in muscle biopsies of patients on statin therapy. J Submicrosc Cytol Pathol. 2004;36(1):85–9. PMID: 15311678; Villa L, Lerario A, Calloni S, Peverelli L, Matinato C, De Liso F, et al. Immune-mediated necrotizing myopathy due to statins exposure. Acta Myol. 2018;37(4):257–62. PMID: 30944904; Somagutta MKR, Shama N, Pormento MKL, Jagani RP, Ngardig NN, Ghazarian K, et al. Statin-induced necrotizing autoimmune myopathy: a systematic review. Reumatologia. 2022;60(1):63–9. https://doi.org/10.5114/reum.2022.114108; https://www.risksafety.ru/jour/article/view/391

الاتاحة: https://www.risksafety.ru/jour/article/view/391
https://doi.org/10.30895/2312-7821-2023-11-3-252-270

المؤلفون: E. O. Kochkina, N. V. Verlan, Е. О. Кочкина, Н. В. Верлан

المساهمون: The study was performed without external funding., Работа выполнена без спонсорской поддержки

المصدر: Safety and Risk of Pharmacotherapy; Том 11, № 3 (2023); 271-278 ; Безопасность и риск фармакотерапии; Том 11, № 3 (2023); 271-278 ; 2619-1164 ; 2312-7821

مصطلحات موضوعية: безопасность лекарственных средств, statins, atorvastatin, simvastatin, myopathy, rhabdomyolysis, adverse drug reactions, spontaneous reports, pharmacovigilance, drug safety, статины, аторвастатин, симвастатин, миопатия, рабдомиолиз, нежелательные реакции, спонтанные сообщения, фармаконадзор

وصف الملف: application/pdf

Relation: https://www.risksafety.ru/jour/article/view/377/878; https://www.risksafety.ru/jour/article/downloadSuppFile/377/368; https://www.risksafety.ru/jour/article/downloadSuppFile/377/405; Кухарчук ВВ, Ежов МВ, Сергиенко ИВ, Арабидзе ГГ, Бубнова МГ, Балахонова ТВ и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VII пересмотр. Атеросклероз и дислипидемии. 2020;(1):7–40. https://doi.org/10.34687/2219-8202.JAD.2020.01.0002; Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;2013(1):CD004816. https://doi.org/10.1002/14651858.CD004816.pub5; Noyes AM, Thompson PD. The effects of statins on exercise and physical activity. J Clin Lipidol. 2017;11(5):1134–44. https://doi.org/10.1016/j.jacl.2017.07.003; Janssen L, Allard NAE, Saris CGJ, Keijer J, Hopman MTE, Timmers S. Muscle toxicity of drugs: when drugs turn physiology into pathophysiology. Physiol Rev. 2020;100(2):633–72. https://doi.org/10.1152/physrev.00002.2019; Сычев ДА, Остроумова ОД, Переверзев АП, ред. Лекарственнo-индуцированные заболевания. Т. I. М.: Прометей; 2022.; Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45. https://doi.org/10.1038/clpt.1981.154; Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, et al. Statin-associated muscle symptoms: impact on statin therapy — European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;36(17):1012–22. https://doi.org/10.1093/eurheartj/ehv043; Дядык АИ, Куглер ТЕ, Сулиман ЮВ, Зборовский СР, Здиховская ИИ. Побочные эффекты статинов: механизмы развития, диагностика, профилактика и лечение. Архивъ внутренней медицины. 2018;8(4):266–76. https://doi.org/10.20514/2226-6704-2018-8-4-266-276; Соболева НИ. Нежелательные побочные эффекты статинов в терапии пациентов старшего возраста. Клиническая геронтология. 2020;(5–6):34–8. EDN: EDQXAB; Miettinen TA, Pyörälä K, Olsson AG, Musliner TA, Cook TJ, Faergeman O, et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation. 1997;96(12):4211–8. https://doi.org/10.1161/01.cir.96.12.4211; Heart Protection Study Collaborative Group. MRC/ BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7–22. https://doi.org/10.1016/S0140-6736(02)09327-3; Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–88. https://doi.org/10.1093/eurheartj/ehz455; Norata GD, Tibolla G, Catapano AL. Targeting PCSK9 for hypercholesterolemia. Annu Rev Pharmacol Toxicol. 2014;54:273–93. https://doi.org/10.1146/annurev-pharmtox-011613-140025; Korman MJ, Retterstøl K, Kristiansen IS, Wisløff T. Are PCSK9 inhibitors cost effective? Pharmacoeconomics. 2018;36(9):1031–41. https://doi.org/10.1007/s40273-018-0671-0; https://www.risksafety.ru/jour/article/view/377

الاتاحة: https://www.risksafety.ru/jour/article/view/377
https://doi.org/10.30895/2312-7821-2023-11-3-271-278

المؤلفون: Андрей Сергеевич Галенко, Ксения Дмитриевна Охотникова, Александр Александрович Иванов, Сергей Андреевич Корепин, Александра Александровна Холкина, Яна Вячеславовна Соусова, Елена Анатольевна Андреева

المصدر: University Therapeutic Journal, Vol 4, Iss 3 (2022)

مصطلحات موضوعية: рабдомиолиз, статины, гипокалиемия, клинический случай, Medicine

وصف الملف: electronic resource

Relation: http://ojs3.gpmu.org/index.php/Un-ther-journal/article/view/4122; https://doaj.org/toc/2713-1912; https://doaj.org/toc/2713-1920

URL الوصول: https://doaj.org/article/07963532665945e0bfa2b46ce6aa6327

المؤلفون: O. V. Gaisenok, Yu. M. Chichkov, M. V. Leonova, О. В. Гайсёнок, Ю. М. Чичков, М. В. Леонова

المصدر: Rational Pharmacotherapy in Cardiology; Vol 18, No 5 (2022); 585-590 ; Рациональная Фармакотерапия в Кардиологии; Vol 18, No 5 (2022); 585-590 ; 2225-3653 ; 1819-6446

مصطلحات موضوعية: рабдомиолиз, ticagrelor, drug-drug interactions, side effects, rhabdomyolysis, тикагрелор, межлекарственные взаимодействия, побочные эффекты

وصف الملف: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2827/2365; World Health Organization: Cardiovascular diseases (CVDs). Key facts [cited 2021 Aug 10]. Available from: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds).; Roy D, Mahapatra T, Manna K, et al. Comparing effectiveness of high-dose Atorvastatin and Rosuvastatin among patients undergone Percutaneous Coronary Interventions: A non-concurrent cohort study in India. PLoS One. 2020;15(5):e0233230. DOI:10.1371/journal.pone.0233230.; Chou R, Dana T, Blazina I, et al. Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2016;316(19):2008-2024. DOI:10.1001/jama.2015.15629.; Newman CB, Preiss D, Tobert JA, et al.; American Heart Association Clinical Lipidology, Lipoprotein, Metabolism and Thrombosis Committee, a Joint Committee of the Council on Atherosclerosis, Thrombosis and Vascular Biology and Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular Disease in the Young; Council on Clinical Cardiology; and Stroke Council. Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2019;39(2):e38-e81. DOI:10.1161/ATV.0000000000000073.; Ould-Nana I, Cillis M, Gizzi M, et al. Rhabdomyolysis and acute kidney injury induced by the association of rosuvastatin and abiraterone: A case report and review of the literature. J Oncol Pharm Pract. 2021;27(1):216-9. DOI:10.1177/1078155220923001.; Miller PE, Martin SS. Approach to Statin Use in 2016: an Update. Curr Atheroscler Rep. 2016;18(5):20. DOI:10.1007/s11883-016-0578-1.; Collet JP, Thiele H, Barbato E, et al.; ESC Scientific Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289-367. DOI:10.1093/eurheartj/ehaa575; Kido K, Wheeler MB, Seratnahaei A, et al. Rhabdomyolysis precipitated by possible interaction of ticagrelor with high-dose atorvastatin. J Am Pharm Assoc (2003). 2015;55(3):320-3. DOI:10.1331/JAPhA.2015.14151.; Banakh I, Haji K, Kung R, et al. Severe Rhabdomyolysis due to Presumed Drug Interactions between Atorvastatin with Amlodipine and Ticagrelor. Case Rep Crit Care. 2017;2017:3801819. DOI:10.1155/2017/3801819.; Samuel G, Atanda AC, Onyemeh A, et al. A Unique Case of Drug Interaction between Ticagrelor and Statin Leading to Acute Renal Failure. Cureus. 2017;9(8):e1633. DOI:10.7759/cureus.1633.; Mrotzek SM, Rassaf T, Totzeck M. Ticagrelor Leads to Statin-Induced Rhabdomyolysis: A Case Report. Am J Case Rep. 2017;18:1238-41. DOI:10.12659/ajcr.905974.; New J, Le K, Wong K, et al. A case of acute renal failure and rhabdomyolysis associated with the concomitant use of Ticagrelor, Rosuvastatin and Losartan. JMS Intern Med 2017;2:1004 [cited 2021 Aug 14]. Available from: https://www.jscimedcentral.com/InternalMedicine/internalmedicine-2-1004.pdf.; Park IS, Lee SB, Song SH, et al. Ticagrelor-induced acute kidney injury can increase serum concentration of statin and lead to concurrence of rhabdomyolysis. Anatol J Cardiol. 2018;19(3):225-6. DOI:10.14744/AnatolJCardiol.2017.8200.; Sarinic VM, Sandberg L, Hartman J, Caduff-Janosa P. Interaction between rosuvastatin and ticagrelor resulting in rhabdomyolysis. WHO Pharm Newsl. 2018;3:10-4 [cited 2021 Aug 10]. Available from: https://www.who-umc.org/media/164007/rhabdomyolysisweb.pdf.; Danielak D, Karaźniewicz-Łada M, Główka F. Assessment of the Risk of Rhabdomyolysis and Myopathy During Concomitant Treatment with Ticagrelor and Statins. Drugs. 2018;78(11):1105-12. DOI:10.1007/s40265-018-0947-x.; Martín Navarro JA, Gutiérrez Sánchez MJ, Petkov Stoyanov V, Jiménez Herrero MC. Acute renal failure secondary to rhabdomyolysis in a patient receiving treatment with ticagrelor and atorvastatin. Nefrologia (Engl Ed). 2019;39(4):448-50. DOI:10.1016/j.nefro.2018.10.012.; Sibley RA, Katz A, Papadopoulos J. The Interaction Between Rosuvastatin and Ticagrelor Leading to Rhabdomyolysis: A Case Report and Narrative Review. Hosp Pharm. 2021;56(5):537-42. DOI:10.1177/0018578720928262.; Mach F, Baigent C, Catapano AL, et al.; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-88. DOI:10.1093/eurheartj/ehz455.; Furtado RHM, Giugliano RP. What Lessons Have We Learned and What Remains to be Clarified for PCSK9 Inhibitors? A Review of FOURIER and ODYSSEY Outcomes Trials. Cardiol Ther. 2020;9(1):59-73. DOI:10.1007/s40119-020-00163-w.; Kariyanna PT, Haseeb S, Chowdhury YS, et al. Ticagrelor and Statin Interaction Induces Rhabdomyolysis and Acute Renal Failure: Case reports and Scoping Review. Am J Med Case Rep. 2019;7(12):337-41. DOI:10.12691/ajmcr-7-12-9.; Vrkić Kirhmajer M, Macolia Šarinić V, Šimičević L, et al. Rosuvastatin-Induced Rhabdomyolysis - Possible Role of Ticagrelor and Patients' Pharmacogenetic Profile. Basic Clin Pharmacol Toxicol. 2018;123(4):509-18. DOI:10.1111/bcpt.13035.; DiNicolantonio JJ, Serebruany VL. Angiotensin receptor blockers worsen renal function and dyspnea on ticagrelor: a potential ticagrelor-angiotensin receptor blocker interaction? Clin Cardiol. 2012;35(11):647-8. DOI:10.1002/clc.22063.; Cattaneo M, Schulz R, Nylander S. Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance. J Am Coll Cardiol. 2014;63(23):2503-9. DOI:10.1016/j.jacc.2014.03.031.; Modlinger PS, Welch WJ. Adenosine A1 receptor antagonists and the kidney. Curr Opin Nephrol Hypertens. 2003;12(5):497-502. DOI:10.1097/00041552-200309000-00003.; Wallentin L, Becker RC, Budaj A, et al, PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045-57. DOI:10.1056/ NEJMoa0904327.; Roth M, Obaidat A, Hagenbuch B. OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br J Pharmacol. 2012;165(5):1260-87. DOI:10.1111/j.1476-5381.2011.01724.x.; Dobesh PP, Oestreich JH. Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety. Pharmacotherapy. 2014;34(10):1077-90. DOI:10.1002/phar.1477.; Goard CA, Mather RG, Vinepal B, et al. Differential interactions between statins and P-glycoprotein: implications for exploiting statins as anticancer agents. Int J Cancer. 2010;127(12):2936-48. DOI:10.1002/ijc.25295.; El Kantar S, Nehmeh B, Saad P, et al. Derivatization and combination therapy of current COVID-19 therapeutic agents: a review of mechanistic pathways, adverse effects, and binding sites. Drug Discov Today. 2020;25(10):1822-38. DOI:10.1016/j.drudis.2020.08.002.; Mallhi TH, Khan YH, Adnan AS. Stratification of Acute Kidney Injury in COVID-19. Am J Trop Med Hyg. 2020;103(6):2164-7. DOI:10.4269/ajtmh.20-0794.; Aygün İ, Kaya M, Alhajj R. Identifying side effects of commonly used drugs in the treatment of Covid 19. Sci Rep. 2020;10(1):21508. DOI:10.1038/s41598-020-78697-1.; Varenhorst C, Eriksson N, Johansson Å, et al, PLATO Investigators. Effect of genetic variations on ticagrelor plasma levels and clinical outcomes. Eur Heart J. 2015;36(29):1901-12. DOI:10.1093/eurheartj/ehv116.; Liu JE, Liu XY, Chen S, et al. SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case-control study. Eur J Clin Pharmacol. 2017;73(11):1409-16. DOI:10.1007/s00228-017-2318-z.; Gaisenok O. Pandemic of Fear or what Statistics Hide: Patients with Cardiovascular Disease are at Increased Risk During COVID-19. International Cardiovascular Forum Journal. 2020;21:2-6. DOI:10.17987/icfj.v21i0.711.; Stevens PE, Levin A; Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158(11):825-30. DOI:10.7326/0003-4819-158-11-201306040-00007.; https://www.rpcardio.com/jour/article/view/2827

الاتاحة: https://www.rpcardio.com/jour/article/view/2827
https://doi.org/10.20996/1819-6446-2022-10-03

المؤلفون: A. Shabunin V., S. Loginov P., P. Drozdov A., I. Nesterenko V., D. Makeev A., O. Zhuravel S., L. Karapetyan R., А. Шабунин В., С. Логинов П., П. Дроздов А., И. Нестеренко В., Д. Макеев А., О. Журавель С., Л. Карапетян Р.

المصدر: Transplantologiya. The Russian Journal of Transplantation; Том 13, № 2 (2021); 158-164 ; Трансплантология; Том 13, № 2 (2021); 158-164 ; 2542-0909 ; 2074-0506 ; 10.23873/2074-0506-2021-13-2

مصطلحات موضوعية: liver transplantation, rhabdomyolysis, atorvastatine, cyclosporin, трансплантация печени, рабдомиолиз, статины, аторвастатин, циклоспорин

وصف الملف: application/pdf

Relation: https://www.jtransplantologiya.ru/jour/article/view/573/623; https://www.jtransplantologiya.ru/jour/article/view/573/628; Гоникова З.З., Никольская А.О., Кирсанова Л.А., Шагидулин М.Ю., Онищенко Н.А., Севастьянов В.И. Сравнительный анализ регенераторной активности клеток костного мозга и общей РНК, выделенной из них, при хроническом фиброзирующем повреждении печени. Вестник трансплантологии и искусственных органов. 2019;21(3):100–110. https://doi.org/10.15825/1995-1191-2019-3-100-110; Halliday N, Westbrook RN. Liver transplantation; need, indications, patient selection and pre-transplant care. Br J Hosp Med (Lond). 2017;78(5):252-259 PMID: 28489446 https://doi.org/10.12968/hmed.2017.78.5.252; Готье С.В., Мойсюк Я.Г., Поп цов В.Н., Корнилов М.Н., Ярошенко Е.Б., Погребниченко И.В. и др. Отдаленные результаты трансплантации труп ной печени. Вестник трансплан тологии и искусственных органов. 2014;16(3):45–53. https://doi.org/10.15825/1995-1191-2014-3-45-53; Muñoz LE, Nañez H, Rositas F,Pérez E, Razo S, Cordero P, et al. Long-term complications and survival of patients after orthotopic liver transplantation. Transplant Proc. 2010;42(6):2381–2382. PMID: 20692485 https://doi.org/10.1016/j.transproceed.2010.05.007; Lucey MR, Terrault N, Ojo L, Hay JE, Neuberger J, Blumberg E, et al. Long term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl. 2013;19(1):3–26. PMID: 23281277 https://doi.org/10.1002/lt.23566; Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–188. PMID: 31504418 https://doi.org/10.1093/eurheartj/ehz455; Дядык А.И., Куглер Т.Е., Сули ман Ю.В., Зборовский С.Р., Зди ховская И.И. Побочные эффекты статинов: механизмы развития, диагностика, профилактика и лечение. Архивъ внутренней медицины. 2018;8(4):266–276. https://doi.org/10.20514/2226-6704-2018-8-4-266-276; Драпкина О. М., Чернова Е. М. Миопатия как побочный эффект терапии статинами: механизмы развития и перспективы лечения. Рациональ ная фармакотерапия в кардиологии. 2015;11(1):96–101. https://doi.org/10.20996/1819-6446-2015-11-1-96-101; Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, et al. Statin-associated muscle symptoms: impact on statin therapy – Europe an Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;36(17):1012–1022. PMID: 25694464 https://doi.org/10.1093/eurheartj/ehv043; Cervellin G, Comelli I, Lippi G. Rhabdomyolysis: historical background, clinical, diagnostic and therapeutic features. Clin Chem Lab Med. 2010;48(6):749–56. PMID: 20298139 https://doi.org/10.1515/CCLM.2010.151; European Association for the Study of the Liver. EASL Сlinical practice guidelines: liver transplantation. J Hepatology. 2016;64(2):433–485. https://doi.org/10.1016/j.jhep.2015.10.006; Huang CJ, Chen CL, Wang CS, Cheng KW, Chen KH, Wang CC. Rhabdomyolysis after liver transplantation: a case report. Transplant Proc. 2008;40(8):2821–2822. PMID: 18929870 https://doi.org/10.1016/j.transproceed.2008.07.032; Shahbazov R, Fox M, Alejo J, Anjum MA, Azari F, Doyle A, et al. A case of rhabdomyolysis after kidney transplantation successfully managed with intensive continuous dialysis. J Surg Case Rep. 2018(4):rjy078. PMID: 29765590 https://doi.org/10.1093/jscr/rjy078; Моисеенко А.В., Поликарпов А.А., Гранов Д.А., Таразов П.Г., Шаповал С.В., Шералиев А.Р. и др. Возможности интервенционной радиологии до и послеортотопической трансплантации печени. Вестник трансплантологии и искусственных органов. 2018;20(3):75–79. https://doi.org/10.15825/1995-1191-2018-3-75-79; Готье С.В., Хомяков C.М. Донорство и трансплантация органов в Российской Федерации в 2018 году. XI сообщение регистра Российского трансплантологического общества. Вестник трансплантологии и искусственных органов. 2019;21(3):7–32. https://doi.org/10.15825/1995-1191-2019-3-7-32; Яремин Б.И., Парабина Е.В., Масликова У.В., Александрова В.Э. Острый эпизод рабдомиолиза, связанный с приемом эверолимуса и каберголи на, у реципиентки почки после родов. Трансплантология. 2017;9(4)312–316. https://doi.org/10.23873/2074-0506-2017-9-4-312-316; https://www.jtransplantologiya.ru/jour/article/view/573

الاتاحة: https://www.jtransplantologiya.ru/jour/article/view/573
https://doi.org/10.23873/2074-0506-2021-13-2-158-164

المؤلفون: G. Berdnikov A., N. Kudryashova Y., E. Migunova V., S. Rey I., E. Gurok V., Kh. Abdulamitov K., E. Klychnikova V., O. Maklyayeva G., Г. Бердников А., Н. Кудряшова Е., Е. Мигунова В., С. Рей И., Е. Гурок В., Х. Абдуламитов К., Е. Клычникова В., О. Макляева Г.

المصدر: Russian Sklifosovsky Journal "Emergency Medical Care"; Том 10, № 3 (2021); 452-459 ; Журнал им. Н.В. Склифосовского «Неотложная медицинская помощь»; Том 10, № 3 (2021); 452-459 ; 2541-8017 ; 2223-9022

مصطلحات موضوعية: new coronavirus infection COVID-19, coronavirus SARS-CoV-2, acute kidney injury, scintigraphy, rhabdomyolysis, новая коронавирусная инфекция COVID-19, коронавирус SARS-CoV-2, острое почечное повреждение, сцинтиграфия, рабдомиолиз

وصف الملف: application/pdf

Relation: https://www.jnmp.ru/jour/article/view/1205/968; Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. PMID: 31986264 https://doi.org/10.1016/S0140-6736(20)30183-5; Suwanwongse K, Shabarek N. Rhabdomyolysis as a Presentation of 2019 Novel Coronavirus Disease. Cureus. 2020;12(4):e7561. PMID: 32382463 https://doi.org/10.7759/cureus.7561; Chan KH, Farouji I, Hanoud AA, Slim J. Weakness and elevated creatinine kinase as the initial presentation of coronavirus disease 2019. Am J Emerg Med. 2020;38(7):1548.e1–1548.e3. PMID: 32414522 https://doi.org/10.1016/j.ajem.2020.05.015; Zhang Q, Shan KS, Minalyan A, O’Sullivan C, Nace T. A Rare Presentation of Coronavirus Disease 2019 (COVID-19) Induced Viral Myositis With Subsequent Rhabdomyolysis. Cureus. 2020;12(5):e8074. PMID: 32542129 https://doi.org/10.7759/cureus.8074; Gefen AM, Palumbo N, Nathan SK, Singer PS, Castellanos-Reyes LJ, Sethna CB. Pediatric COVID-19-associated rhabdomyolysis: a case report. Pediatr Nephrol. 2020;35(8):1517–1520. PMID: 32447505 https://doi.org/10.1007/s00467-020-04617-0; Jin M, Tong Q. Rhabdomyolysis as Potential Late Complication Associated with COVID-19. Emerg Infect Dis. 2020;26(7):1618–1620. PMID: 32197060 https://doi.org/10.3201/eid2607.200445; Zutt R, van der Kooi AJ, Linthorst GE, Wanders RJA, de Visser M. Rhabdomyolysis: review of the literature. Neuromuscul Disord. 2014; 24(8):651–659. PMID: 24946698 https://doi.org/10.1016/j.nmd.2014.05.005; Coco TJ, Klasner AE. Drug-induced rhabdomyolysis. Curr Opin Pediatr. 2004;16(2):206–210. PMID: 15021204 https://doi.org/10.1097/00008480-200404000-00017; Huerta-Alardin AL, Varon J, Marik PE. Bench-to-bedside review: Rhabdomyolysis an overview for clinicians. Critl Care. 2005;9(2):158–169. PMID: 15774072 https://doi.org/10.1186/cc2978; Mikkelsen TS, Toft P. Prognostic value, kinetics and effect of CVVHDF on serum of the myoglobin and creatine kinase in critically ill patients with rhabdomyolysis. Acta Anaesthesiol Scand. 2005;49(6):859–864. PMID: 15954972 https://doi.org/10.1111/j.1399-6576.2005.00577; Talaie H, Pajouhmand A, Abdollahi M, Panahandeh R, Emami H, Hajinasrolah S, et al. Rhabdomyolysis among acute human poisoning cases. Hum Exp Toxicol. 2007;26(7):557–561 PMID: 17884958 https://doi.org/10.1177/0960327107078667; Perreault S, Birca A, Piper D, Nadeau A, Gauvin F, Vanasse M. Transient creatine phosphokinase elevations in children: a single-center experience. J Pediatr. 2011;159(4):682–685. PMID: 21592501 https://doi.org/10.1016/j.jpeds.2011.03.045; Rosa NG., Silva G, Teixeira A, Rodrigues F, Araújo JA. Rhabdomyolysis. Acta Med Port. 2005;18(4):271–281. PMID: 16584660; Singh D, Chander V, Chopra K. Rhabdomyolysis. Methods Find Exp Clin Pharmacol. 2005;27(1):39–48. PMID: 15834458 https://doi.org/10.1358/mf.2005.27.1.875435; Crum-Cianflone NF. Bacterial, fungal, parasitic, and viral myositis. Clin Microbiol Rev. 2008;21(3):473–494. PMID: 18625683 https://doi.org/10.1128/CMR.00001-08; Ayala E, Kagawa FT, Wehner JH, Tam J, Upadhyay D. Rhabdomyolysis associated with 2009 influenza A(H1N1). JAMA. 2009;302(17):1863–1864. PMID: 19887664 https://doi.org/10.1001/jama.2009.1582; Fadila MF, Wool KJ. Rhabdomyolysis secondary to influenza a infection: a case report and review of the literature. North Am J Med Sci. 2015;7(3):122–124. PMID: 25839005 https://doi.org/10.4103/1947-2714.153926; Wu VC, Hsueh PR, Lin WC, Huang JW, Tsai HB, Chen YM, et al. Acute renal failure in SARS patients: more than rhabdomyolysis. Nephrol Dial Transplant. 2004;19(12):3180–3182. PMID: 15575009 https://doi.org/10.1093/ndt/gfh436; Chen LL, Hsu CW, Tian YC, Fang JT. Rhabdomyolysis associated with acute renal failure in patients with severe acute respiratory syndrome. Int J Clin Pract. 2005;59(10):1162–1166. PMID: 16178983 https://doi.org/10.1111/j.1368-5031.2005.00540.; Singh U, Scheld WM. Infectious etiologies of rhabdomyolysis: three case reports and review. Clin Infect Dis. 1996;22(4):642–649. PMID: 8729203 https://doi.org/10.1093/clinids/22.4.642; Wen Z, Liang Y, Hao Y, Delavan B, Huang R, Mikailov M, et al. DrugInduced Rhabdomyolysis Atlas (DIRA) for idiosyncratic adverse drug reaction management. Drug Discovery Today. 2019;24(1):9–15. PMID: 29902520 https://doi.org/10.1016/j.drudis.2018.06.006; Liang Y, Wang M-L, Chien C-S, Yarmishyn AA, Yang Y-P, Lai W-Y, et al. Highlight of immune pathogenic response and hematopathologic effect in SARS-CoV, MERS-CoV, and SARS-Cov-2 infection. Front Immunol. 2020;11:1022. PMID: 32574260 https://doi.org/10.3389/fimmu.2020.01022 eCollection 2020.; Гурок Е.А., Синякова О.Г., Александрова И.В., Марченкова Л.В., Кудряшова Н.Е. Сцинтиграфия почек и мягких тканей в диагностике синдрома позиционного сдавления. В кн.: Радиология – 2007: материалы Всерос. конгр. с межд. уч. по лучевой диагностике и лучевой терапии. Москва; 2007. с. 111–112.; Марченкова Л.В., Александрова И.В., Рей С.И., Первакова Э.И., Ильинский М.Е., Донова Л.В., и др. Прогностические факторы развития острой почечной недостаточности и неблагоприятного исхода у больных с синдромом позиционного сдавления мягких тканей. В кн.: Безопасность больного в анестезиологии-реаниматологии: материалы 6-ой науч.-практ. конф. Москва; 2008. с. 47–48.; Марченкова Л.В., Бердников Г.А., Кудряшова Н.Е., Ермолов А.С. Синдром позиционного сдавления. Современные подходы к диагностике и лечению. Медицинский алфавит. Серия Неотложная медицина. 2018;(1):8–12.; Chan KH, Slim J. Rhabdomyolysis as Potential Late Complication Associated with COVID-19. Emerg Infect Dis. 2020;26(10):2535. PMID: 32614765 https://doi.org/10.3201/eid2610.202225; Chiba N, Matsuzaki M, Mawatari T, Mizuochi M, Sakurai A, Kinoshita K. Beneficial effects of dantrolene in the treatment of rhabdomyolysis as a potential late complication associated with COVID-19: a case report. Eur J Med Res. 2021;26(1):18. PMID: 33557936 https://doi.org/10.1186/s40001-021-00489-8; https://www.jnmp.ru/jour/article/view/1205

الاتاحة: https://www.jnmp.ru/jour/article/view/1205
https://doi.org/10.23934/2223-9022-2021-10-3-452-459

المؤلفون: N. A. Rumyantsev, Yu. V. Olefir, V. G. Kukes

المصدر: Безопасность и риск фармакотерапии, Vol 5, Iss 4, Pp 170-173 (2018)

مصطلحات موضوعية: ген slco1b1, эффективность и безопасность, фармакогенетика, миопатия, рабдомиолиз, статины, персонализированная медицина, gene slco1b1, efficacy and safety, pharmacogenetics, myopathy, rhabdomyolysis, statins, personalized medicine, Therapeutics. Pharmacology, RM1-950

وصف الملف: electronic resource

Relation: https://www.risksafety.ru/jour/article/view/87; https://doaj.org/toc/2312-7821; https://doaj.org/toc/2619-1164

URL الوصول: https://doaj.org/article/656f2e3c3b8b460e8bcbb516642c95d3

المؤلفون: Kazakov A.S., Darmostukova M.A., Bukatina T.M., Snegireva I.I., Lepakhin V.K., Zatolochina K.E.

المصدر: Безопасность и риск фармакотерапии

مصطلحات موضوعية: лекарственное взаимодействие, Drug-drug interaction, rhabdomyolysis, myopathy, colchicine, statins, рабдомиолиз, миопатия, колхицин, статины

Relation: https://doi.org/10.30895/2312-7821-2018-6-3-118-122; https://openrepository.ru/article?id=245656

الاتاحة: https://openrepository.ru/article?id=245656

المؤلفون: Kruchinin, E. V., Lebedev, I. A., Mokin, E. A., Kozlov, M. V., Alekberov, R. I., Lukashenok, A. V., Pusikova, A. A., Nebesova, A. A., Shusharin, N. R., Seypilov, A. A., Smetanin, E. I., Podkorytova, O. M., Кручинин, Е. В., Лебедев, И. А., Мокин, Е. А., Козлов, М. В., Алекберов, Р. И., Лукашенок, А. В., Пусикова, А. А., Небесова, А. А., Шушарин, Н. Р., Сейпилов, А. А., Сметанин, Е. И., Подкорытова, О. М.

مصطلحات موضوعية: HAFF DISEASE, RHABDOMYOLYSIS, YUKSOVSKY-SARTLANSKY DISEASE, ГАФФСКАЯ БОЛЕЗНЬ, РАБДОМИОЛИЗ, ЮКСОВСКО-САРТЛАНТСКАЯ БОЛЕЗНЬ

وصف الملف: application/pdf

Relation: Уральский медицинский журнал. 2019. № 13(181).; Эколого-гигиенические факторы развития Гаффской болезни в Тюменской области / Е. В. Кручинин, И. А. Лебедев, Е. А. Мокин [и др.]. – Текст: электронный // Уральский медицинский журнал. - 2019. – № 13(181). – С. 118-122.; http://elib.usma.ru/handle/usma/18788

الاتاحة: http://elib.usma.ru/handle/usma/18788

المؤلفون: S. Bardakov N., A. Belskykh N., N. Ryzhman N., I. Zheleznyak S., S. Bagnenko S., V. Tsargush A., A. Emelyantsev A., G. Romanov G., M. Mavllikeev O., R. Deev V., С. Бардаков Н., А. Бельских Н., Н. Рыжман Н., И. Железняк С., С. Багненко С., В. Царгуш А., А. Емельянцев А., Г. Романов Г., М. Мавликеев О., Р. Деев В.

المصدر: Diagnostic radiology and radiotherapy; № 2 (2019); 91-101 ; Лучевая диагностика и терапия; № 2 (2019); 91-101 ; 2079-5343 ; 10.22328/2079-5343-2019-2

مصطلحات موضوعية: acute compartment syndrome, postexercise rhabdomyolysis, muscle MRI, extracorporeal hemocorrection, острый компартмент-синдром, постнагрузочный рабдомиолиз, МРТ мышц, экстракорпоральная гемокоррекция

وصف الملف: application/pdf

Relation: https://radiag.bmoc-spb.ru/jour/article/view/419/350; Long S. et al. Multimodality imaging findings in rhabdomyolysis and a brief review of differential diagnoses // Emerg. Radiol. 2017. Vol. 24 (4). P. 387–392.; Beetham R. Biochemical investigation of suspected rhabdomyolysis // Ann. Clin. Biochem. 2000. Vol. 37 (Pt 5). P. 581–587.; Jabur W.L. et al. An Observational Epidemiological Study of Exerciseinduced Rhabdomyolysis Causing Acute Kidney Injury: A Singlecenter Experience // Indian J. Nephrol. 2018. Vol. 28 (2). P. 101–104.; Huerta-Alardin A.L., Varon J., Marik P.E. Bench-to-bedside review: Rhabdomyolysis — an overview for clinicians // Crit Care. 2005. Vol. 9 (2). P. 158–169.; Lappalainen H. et al. Elimination kinetics of myoglobin and creatine kinase in rhabdomyolysis: implications for follow-up // Crit Care Med. 2002. Vol. 30 (10); Pierson E.H., Bantum B.M., Schaefer M.P. Exertional rhabdomyolysis of the elbow flexor muscles from weight lifting // Pmr. 2014. Vol. 6 (6). P. 556–559.; Mattiassich G. et al. Paravertebral compartment syndrome after training causing severe back pain in an amateur rugby player: report of a rare case and review of the literature // BMC Musculoskelet Disord. 2013. Vol. 14. P. 259.; Kok S.X.S., Tan T.J. Clinics in diagnostic imaging (179). Severe rhabdomyolysis complicated by myonecrosis // Singapore Med. J. 2017. Vol. 58 (8). P. 467–472.; Melli G., Chaudhry V., Cornblath D.R. Rhabdomyolysis: an evaluation of 475 hospitalized patients // Medicine (Baltimore). 2005. Vol. 84 (6). P. 377–385.; Ji J.W. Acute Compartment Syndrome Which Causes Rhabdomyolysis by Carbon Monoxide Poisoning and Sciatic Nerve Injury Associated with It: A Case Report // Hip Pelvis. 2017. Vol. 29 (3). P. 204–209.; Shellock F.G. et al. Acute effects of exercise on MR imaging of skeletal muscle: concentric vs eccentric actions // AJR Am. J. Roentgenol. 1991. Vol. 156 (4). P. 765–768.; Vanholder R. et al. Rhabdomyolysis // J. Am. Soc. Nephrol. 2000. Vol. 11 (8). P. 1553–1561.; Tibana R.A., Sousa N.M.F. Exertional Rhabdomyolysis after an Extreme Conditioning Competition. A Case Report. 2018. Vol. 6 (2).; Moratalla M.B., Braun P., Fornas G.M. Importance of MRI in the diagnosis and treatment of rhabdomyolysis // Eur. J. Radiol. 2008. Vol. 65 (2). P. 311–315.; Mehta P. et al. Magnetic Resonance Imaging of Musculoskeletal Emergencies // Semin Ultrasound CT MR. 2017. Vol. 38 (4). P. 439–452.; May D.A. et al. Abnormal signal intensity in skeletal muscle at MR imaging: patterns, pearls, and pitfalls // Radiographics. 2000. Vol. 20 Spec. No. P. 295–315.; De Meijer A.R. et al. Serum creatine kinase as predictor of clinical course in rhabdomyolysis: a 5-year intensive care survey // Int. Care Med. 2003. Vol. 29 (7). P. 1121–1125.; Takeda S. et al. Two cases of unidentified acute compartment syndrome // BMJ Case Rep. 2018. Vol. January 2018.; Hargens A.R. et al. Quantitation of skeletal-muscle necrosis in a model compartment syndrome // J. Bone Joint Surg Am. 1981. Vol. 63 (4). P. 631–636.; Whitesides T.E. et al. Tissue pressure measurements as a determinant for the need of fasciotomy // Clin Orthop Relat Res. 1975. Vol. 113. P. 43–51.; Lamminen, A.E. et al. Acute rhabdomyolysis: evaluation with magnetic resonance imaging compared with computed tomography and ultrasonography // Br. J. Radiol. 1989. Vol. 62 (736). P. 326–330.; Nakahara K. et al. The value of computed tomography and magnetic resonance imaging to diagnose rhabdomyolysis in acute renal failure // Nephrol. Dial. Transplant. 1999. Vol. 14 (6). P. 1564–1567.; Kakuda W. et al. Rhabdomyolysis lesions showing magnetic resonance contrast enhancement // J. Neuroimaging. 1999. Vol. 9 (3). P. 182–184.; Yeon E.K. et al. Characteristic MR image finding of squatting exercise-induced rhabdomyolysis of the thigh muscles // Br. J. Radiol. 2017. Vol. 90 (1072). Р. 20160740.; Theodorou, D.J., S.J. Theodorou, and Y. Kakitsubata, Skeletal muscle disease: patterns of MRI appearances // Br. J. Radiol. 2012. Vol. 85 (1020). P. e1298–1308.; Lu C.H. et al. Rhabdomyolysis: magnetic resonance imaging and computed tomography findings // J. Comput Assist Tomogr. 2007. Vol. 31 (3). P. 368–374.; Fleckenstein J.L. et al. Acute effects of exercise on MR imaging of skeletal muscle in normal volunteers // AJR Am. J. Roentgenol. 1988. Vol. 151 (2). P. 231–237.; Shintani S., Shiigai T. Repeat MRI in acute rhabdomyolysis: correlation with clinicopathological findings // J. Comput. Assist. Tomogr. 1993. Vol. 17 (5). P. 786–791.; https://radiag.bmoc-spb.ru/jour/article/view/419

الاتاحة: https://radiag.bmoc-spb.ru/jour/article/view/419
https://doi.org/10.22328/2079-5343-2019-10-2-91-101

مصطلحات موضوعية: скелетная мышца, цитокины, синдром длительного сдавливания, cytokines, гиалуроновая кислота, hyaluronic acid, rhabdomyolysis, рабдомиолиз, crush syndrome, skeletal muscle, компрессионная травма, системная воспалительная реакция, compression injury, systemic inflammatory response syndrome

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::251facac02365d2066d16848b828caf3

المؤلفون: O. M. Drapkina, E. M. Chernova

المصدر: Рациональная фармакотерапия в кардиологии, Vol 11, Iss 1, Pp 96-101 (2015)

مصطلحات موضوعية: статины, миопатия, рабдомиолиз, коэнзим Q10, Therapeutics. Pharmacology, RM1-950, Diseases of the circulatory (Cardiovascular) system, RC666-701

وصف الملف: electronic resource

Relation: http://www.rpcardio.ru/jour/article/view/67; https://doaj.org/toc/1819-6446; https://doaj.org/toc/2225-3653

URL الوصول: https://doaj.org/article/da79ff9a638d43deb2f5c7f8c7582b61

المؤلفون: L.M. Trepet, M.M. Pylypenko, O.Yu. Yelska, M.V. Bondar, O.A. Polonevich, G.S. Trepet, M.M. Prokopiv

المصدر: МЕДИЦИНА НЕВІДКЛАДНИХ СТАНІВ; Том 16, № 2 (2020); 87-94
МЕДИЦИНА НЕОТЛОЖНЫХ СОСТОЯНИЙ; Том 16, № 2 (2020); 87-94
EMERGENCY MEDICINE; Том 16, № 2 (2020); 87-94

مصطلحات موضوعية: medicine.medical_specialty, business.industry, 030208 emergency & critical care medicine, Gastroenterology, ethyl alcohol, chronic alcoholism, Wernicke-Korsakoff syndrome, acute cerebrovascular accident, compartment syndrome, acute renal failure, rhabdomyolysis, creatine phosphokinase, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Chronic alcoholism, medicine, этиловый алкоголь, хронический алкоголизм, синдром Вернике — Корсакова, острое нарушение мозгового кровообращения, синдром позиционного сдавления, острая почечная недостаточность, рабдомиолиз, креатинфосфокиназа, етиловий алкоголь, хронічний алкоголізм, синдром Верніке — Корсакова, гостре порушення мозкового кровообігу, синдром позиційного стиснення, гостра ниркова недостатність, рабдоміоліз, креатинфосфокіназа, 030212 general & internal medicine, business

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::311f58e31253c953815ed4ee32189b08
https://doi.org/10.22141/2224-0586.16.2.2020.203152

المؤلفون: N. Rumyantsev A., Yu. Olefir V., V. Kukes G., Н. Румянцев А., Ю. Олефир В., В. Кукес Г.

المصدر: Safety and Risk of Pharmacotherapy; Том 5, № 4 (2017); 170-173 ; Безопасность и риск фармакотерапии; Том 5, № 4 (2017); 170-173 ; 2619-1164 ; 2312-7821 ; undefined

مصطلحات موضوعية: ген SLCO1B1, эффективность и безопасность, фармакогенетика, миопатия, рабдомиолиз, статины, персонализированная медицина, gene SLCO1B1, efficacy and safety, pharmacogenetics, myopathy, rhabdomyolysis, statins, personalized medicine

وصف الملف: application/pdf

Relation: https://www.risksafety.ru/jour/article/view/87/88; Brugts JJ, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009; 338: 2376.; Романов БК. Кальциевая регуляция активности лизосомальных ферментов миокарда. Биомедицинская химия 2005; 51(6): 634-42.; Романов БК, Торопова ИИ, Колесникова ЕЮ. Неправильное применение лекарственных средств. Безопасность и риск фармакотерапии 2014; 2 (3): 28-30.; Ruiz Maldonado JM, Lumbreras B, Muñoz Jimenez H, Navarrete Carranza JM, Anza Aguirrezabala I, Pastor-Valero M. A pilot study in a community pharmacy to determine the efficiency and the effectiveness of statin prescriptions. Aten Primaria 2015; 47(5): 294-300.; Leuschen J, Mortensen EM, Frei CR. Association of statin use with cataracts: a propensity score-matched analysis. JAMA Ophthalmology 2013; 131(11): 1427-34.; Carr DF, O’Meara H, Jorgensen AL. SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink. Clin Pharamachol Ther 2013; 94(6): 695-771.; Солодун МВ, Якушин СС. Особенности гиполипидемической терапии аторвастатином при инфаркте миокарда с позиций персонализированной медицины. РФК 2015; (1): 31-5.; Ромодановский ДП, Горячев ДВ. Планирование и оценка исследований биоэквивалентности препаратов розувастатина. Ведомости Научного центра экспертизы средств медицинского применения 2017; 7(3): 142-9.; Сычев ДА. Рекомендации по применению фармакогенетического тестирования в клинической практике. Качественная клиническая практика 2011; (1): 3-10.; https://www.risksafety.ru/jour/article/view/87; undefined

الاتاحة: https://www.risksafety.ru/jour/article/view/87

المؤلفون: Т. Chernova M., M. Dubko F., Т. Чернова М., М. Дубко Ф.

المصدر: Meditsinskiy sovet = Medical Council; № 2 (2018); 190-193 ; Медицинский Совет; № 2 (2018); 190-193 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2018-2

مصطلحات موضوعية: parvovirus В19, infection, сarditis, myositis, rhabdomyolysis, парвовирус В19, инфекция, кардит, миозит, рабдомиолиз

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/2312/2295; Weigel-Kelley KA, Yoder MC, Srivastava A. Recombinant human parvovirus B19 vectors: erythrocyte P antigen is necessary but not sufficient for successful transduction of human hematopoietic cell. J. Virol 2001, 75: 4110-4116.; Brown KE, Hibbs JR, Gallinella G, Anderson SM, Lehman ED, McCarthy P, et al. Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen). N Engl J Med 1994; 330:1192–6.poietic cells. J. Virol., 2001, 75: 4110-6.; Lunardi C, Tinazzi E, Bason C et al. Human parvovirus B19 infection and autoimmunity. Autoimmun Rev, 200, 8(2): 116-20.; Lefrère JJ, Servant-Delmas A, Candotti D et al. Persistent B19 infection in immunocompetent individuals: implications for transfusion safety. Blood, 2005, 106: 2890-2895.; Broliden K, Tolfvenstam T, Norbeck O. Clinical aspects of parvovirus B19 infection. J Intern. Med., 2006, 260: 285-304.; Парвовирусные инфекции: клиническая картина, общие сведения. http://humbio.ru/humbio/vir4pdd/000a11f7.htm.; Parvovirus B19 Infection http://emedicine.medscape.com/article/961063-overview#a6.; Lunardi C, Tiso M, Borgato L et al. Chronic parvovirus B19 infection induces the production of anti-virus antibodies with autoantigen binding properties. Eur. J. Immunol., 1998, 28: 936-48.; Инфекционная эритема (пятая болезнь). http://humbio.ru/humbio/infect_har/001fc3e6.htm.; Luo Y, Qiu J. Human parvovirus B19: a mechanistic overview of infection and DNA replication. Future Virol, 2015, 10(2): 155-167.; Molina KM, Garcia X, Denfield SW et al. Parvovirus B19 myocarditis causes significant morbidity and mortality in children. Pediatric Cardiology, 34(2): 390-397.; Munro K, Croxson MC, Thomas S et al. Three cases of myocarditis in childhood associated with human parvovirus (B19 virus). Pediatric cardiology, 2013, 24(5): 473-475.; B19 Infection Clinical Presentation. http://emedicine.medscape.com/article/961063-clinical; Scanff JL, Vighetto A, Mekki Y et al. Acute ophthalmoparesis associated with human parvovirus B19 infection. Eur. J. Ophthalmol., 2010, 20(4): 802-804.; Oliver ND, Millar A, Pendleton A. A Case Report on Parvovirus B19 associated myositis. Case reports in Rheumatology. 2012, article ID 250537, 2 pages.; Kishore J, Singh J. Detection of parvovirus B19 in a case of erythema infectiosum with myositis. Indian Pediatrics, 2006, 43: 814-817.; Koliou M, Karaoli E, Soteriades ES et al. Acute hepatitis and myositis associated with erythema infectiosum by parvovirus B19 in an adolescent. BMC Pediatr, 2014, 14: 6.; Ishikawa A, Yoto Y, Ohya K et al. Rhabdomyo lysis associated with human parvovirus B19 infection in a patient with Fukuyama-type congenital muscular dystrophy. J. Child. Neurol., 2014, 29(7): 977-9.; Парвовирусные инфекции: патогенез. http://humbio.ru/humbio/infect_har/00300d07.htm#001fc3e6.htm.; https://www.med-sovet.pro/jour/article/view/2312

الاتاحة: https://www.med-sovet.pro/jour/article/view/2312
https://doi.org/10.21518/2079-701X-2018-2-190-193

المؤلفون: Pascale de Lonlay, Asmaa Mamoune, Yamina Hamel, Michel Bahuau, Sabrina Vergnaud, Moniqu Piraud, Lætitia Lallemand, Marie-Ange Nguyen More, Mai Thao Vio, Norma Beatriz Romero, Monique Piraud, Marie-Ange Ngu Nguyen Morel, Mai Thao Viou

المصدر: Neuromuscular Diseases; Том 5, № 1 (2015); 10-18 ; Нервно-мышечные болезни; Том 5, № 1 (2015); 10-18 ; 2413-0443 ; 2222-8721 ; 10.17650/2222-8721-2015-5-1

مصطلحات موضوعية: статины, fever, temperature-dependent rhabdomyolysis, inherited rhabdomyolysis, environment, thermolability, aldolase A, myopathy, myoglobinuria, pro-inflammatory mediators, hemolytic anemia, myositis, ATP, statins, lipid droplets, лихорадка, термочувствительный рабдомиолиз, наследственный рабдомиолиз, окружающая среда, термолабильность, альдолаза А, миопатия, миоглобинурия, провоспалительные медиаторы, гемолитическая анемия, миозит, аденозинтрифосфат

وصف الملف: application/pdf

Relation: https://nmb.abvpress.ru/jour/article/view/105/106; Sauret J.M., Marinides G., Wang G.K. Rhabdomyolysis. Am Fam Physician 2002;65(5):907– 12.; Brown C.V., Rhee P., Chan L. et al. Preventing renal failure in patients with rhabdomyolysis: do bicarbonate and mannitol make a difference? J Trauma 2004;56(6):1191–6.; Alpers J.P., Jones L.K. Jr. Natural history of exertional rhabdomyolysis: a populationbased analysis. Muscle Nerve 2010;42(4): 487–91.; Perreault S., Birca A., Piper D., et al. Transient creatine phosphokinase elevations in children: a single-center experience. J Pediatr. 2011 Oct;159(4):682–5.; Mackay M.T., Kornberg A.J., Shield L.K. et al. Benign acute childhood myositis: laboratory and clinical features. Neurology 1999;53(9):2127–31.; Zutt R., van der Kooi A.J., Linthorst G.E. et al. Rhabdomyolysis: review of the literature. Neuromuscul Disord 2014;24(8):651–9.; Tein I., DiMauro S., DeVivo D.C. Recurrent childhood myoglobinuria. Adv Pediatr 1990;37:77–117.; Tonin P., Lewis P., Servidei S. et al. Metabolic causes of myoglobinuria. Ann Neurol 1990;27(2):181–5.; Berardo A., DiMauro S., Hirano M. A diagnostic algorithm for metabolic myopathies. Curr Neurol Neurosci Rep 2010;10(2):118–26.; DiMauro S., Garone C., Naini A. Metabolic myopathies. Curr Rheumatol Rep 2010;12(5):386–93.; Laforêt P., Vianey-Saban C. Disorders of muscle lipid metabolism: diagnostic and therapeutic challenges. Neuromuscul Disord 2010;20(11):693–700.; Zeharia A., Shaag A., Houtkooper R.H. et al. Mutations in LPIN1 cause recurrent acute myoglobinuria in childhood. Am J Hum Genet 2008;83(4):489–94.; Michot C., Hubert L., Brivet M. et al. LPIN1 gene mutations: a major cause of severe rhabdomyolysis in early childhood. Hum Mutat 2010;31(7):E1564–73.; Michot C., Hubert L., Romero N.B. et al. Study of LPIN1, LPIN2 and LPIN3 in rhabdomyolysis and exercise-induced myalgia. J Inherit Metab Dis 2012;35(6):1119–28.; Kapina V., Sedel F., Truffert A. et al. Relapsing rhabdomyolysis due to peroxisomal alpha-methylacyl-coa racemase deficiency. Neurology 2010;75(14):1300–2.; Darras B.T., Friedman N.R. Metabolic myopathies: a clinical approach; part I. Pediatr Neurol 2000;22(2):87–97.; Quinlivan R., Jungbluth H. Myopathic causes of exercise intolerance with rhabdomyolysis. Dev Med Child Neurol 2012; 54(10):886–91.; Rosenberg H., Davis M., James D. et al. Malignant hyperthermia. Orphanet J Rare Dis 2007;2:21.; Shapiro M.L., Baldea A., Luchette F.A. Rhabdomyolysis in the intensive care unit. J Intensive Care Med 2012;27(6):335–42.; Cervellin G., Comelli I., Lippi G. Rhabdomyolysis: historical background, clinical, diagnostic and therapeutic features. Clin Chem Lab Med 2010;48(6):749–56.; Luck R.P., Verbin S. Rhabdomyolysis: a review of clinical presentation, etiology, diagnosis, and management. Pediatr Emerg Care 2008;24(4):262–8.; Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesitylinked insulin resistance. Science. 1993;259(5091):87–91.; Xu H., Barnes G.T., Yang Q. et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003;112(12): 1821–30.; Weisberg S.P., McCann D., Desai M. et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112(12):1796–808.; Molenaar J.P., Voermans N.C., van Hoeve B.J et al. Fever-induced recurrent rhabdomyolysis due to a novel mutation in the ryanodine receptor type 1 gene. Intern Med J 2014; 44(8):819–20.; East C., Alivizatos P.A., Grundy S.M. et al. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl J Med 1988;318(1):47–8.; Santos J. Jr. Exertional rhabdomyolysis. Potentially life-threatening consequence of intense exercise. JAAPA 1999;12(7):46–9, 53–5.; Hopkins P.M. Malignant hyperthermia: advances in clinical management and diagnosis. Br J Anaesth 2000;85(1):118–28.; Späte U., Schulze P.C. Proinflammatory cytokines and skeletal muscle. Curr Opin Clin Nutr Metab Care 2004;7(3):265–9.; Ostrowski K., Rohde T., Asp S. et al. Chemokines are elevated in plasma after strenuous exercise in humans. Eur J Appl Physiol 2001;84(3):244–5.; Chen X., Xun K., Chen L. et al. TNFalpha, a potent lipid metabolism regulator. Cell Biochem Funct 2009;27(7):407–16.; Feingold K.R., Grunfeld C. Tumor necrosis factor-alpha stimulates hepatic lipogenesis in the rat in vivo. J Clin Invest 1987;80(1):184–90.; Grunfeld C., Adi S., Soued M. et al. Search for mediators of the lipogenic effects of tumor necrosis factor: potential role for interleukin 6. Cancer Res 1990;50(14): 4233–8.; Vallerie S.N., Hotamisligil G.S. The role of JNK proteins in metabolism. Sci Transl Med 2010;2(60):60rv5.; Chen C.W., Lin J., Chu Y.W. iStable: offtheshelf predictor integration for predicting protein stability changes. BMC Bioinformatics 2013;14 Suppl 2:S5.; Yao D.C., Tolan D.R., Murray M.F. et al. Hemolytic anemia and severe rhabdomyolysis caused by compound heterozygous mutations of the gene for erythrocyte/muscle isozyme of aldolase, ALDO A(Arg303X/Cys338Tyr). Blood 2004;103(6):2401–3.; Michot C., Mamoune A., Vamecq J. et al. Combination of lipid metabolism alterations and their sensitivity to inflammatory cytokines in human lipin-1-deficient myoblasts. Biochim Biophys Acta 2013;1832(12):2103–14.; van Adel B.A., Tarnopolsky M.A. Metabolic myopathies: update 2009. J Clin Neuromuscul Dis 2009;10(3):97–121.; Kreuder J., Borkhardt A., Repp R. et al. Brief report: inherited metabolic myopathy and hemolysis due to a mutation in aldolase A. N Engl J Med 1996;334(17):1100–4.; Miwa S., Fujii H., Tani K. et al. Two cases of red cell aldolase deficiency associated with hereditary hemolytic anemia in a Japanese family. Am J Hematol 1981;11(4):425–37.; Beutler E., Scott S., Bishop A. et al. Red cell aldolase deficiency and hemolytic anemia: a new syndrome. Trans Assoc Am Physicians 1973;86:154–66.; Kishi H., Mukai T., Hirono A. et al. Human aldolase A deficiency associated with a hemolytic anemia: thermolabile aldolase due to a single base mutation. Proc Natl Acad Sci USA 1987;84(23):8623–7.; Pacheco P., Vieira-de-Abreu A., Gomes R.N. et al. Monocyte chemoattractant protein-1/CC chemokine ligand 2 controls microtubule-driven biogenesis and leukotriene B4-synthesizing function of macrophage lipid bodies elicited by innate immune response. J Immunol 2007;179(12):8500–8.; Gomes R.N., Figueiredo R.T., Bozza F.A. et al. Increased susceptibility to septic and endotoxic shock in monocyte chemoattractant protein 1/cc chemokine ligand 2-deficient mice correlates with reduced interleukin 10 and enhanced macrophage migration inhibitory factor production. Shock 2006;26(5):457–63.; Beernink P.T., Tolan D.R. Subunit interface mutants of rabbit muscle aldolase form active dimers. Protein Sci 1994;3(9):1383–91.; Takahashi I., Takasaki Y., Hori K. Sitedirected mutagenesis of human aldolase isozymes: the role of Cys-72 and Cys-338 residues of aldolase A and of the carboxyterminal Tyr residues of aldolases A and B. J Biochem 1989;105(2):281–6.; Tsantes A.E., Bonovas S., Travlou A. et al. Redox imbalance, macrocytosis, and RBC homeostasis. Antioxid Redox Signal 2006;8 (7–8):1205–16.; Marinkovic D., Zhang X., Yalcin S. et al. Foxo3 is required for the regulation of oxidative stress in erythropoiesis. J Clin Invest 2007;117(8):2133–44.; Matés J.M, Pérez-Gómez C., Olalla L. et al. Allergy to drugs: antioxidant enzymic activities, lipid peroxidation and protein oxidative damage in human blood. Cell Biochem Funct 2000;18(2):77–84.; Crawford J.H., Isbell T.S., Huang Z. et al. Hypoxia, red blood cells, and nitrite regulate NO-dependent hypoxic vasodilation. Blood 2006;107(2):566–74.; Berendse K., Ebberink M.S., Ijlst L. et al. Arginine improves peroxisome functioning in cells from patients with a mild peroxisome biogenesis disorder. Orphanet J Rare Dis 2013;8:138.; Roth S.D., Schüttrumpf J., Milanov P. et al. Chemical chaperones improve protein secretion and rescue mutant factor VIII in mice with hemophilia A. PLoS One 2012;7(9):e44505.; Senesi P., Luzi L., Montesano A. et al. Betaine supplement enhances skeletal muscle differentiation in murine myoblasts via IGF-1 signaling activation. J Transl Med 2013; 11:174.; https://nmb.abvpress.ru/jour/article/view/105

الاتاحة: https://nmb.abvpress.ru/jour/article/view/105
https://doi.org/10.17650/2222-8721-2015-1-10-18

المؤلفون: Pascale, De, Asmaa, Mamoune, Yamina, Hamel, Michel, Bahuau, Sabrina, Vergnaud, Monique, Piraud, Lætitia, Lallemand, Marie-ange, Nguyen, Mai, Thao, Norma, Beatriz

مصطلحات موضوعية: РАБДОМИОЛИЗ,ЛИХОРАДКА,ТЕРМОЧУВСТВИТЕЛЬНЫЙ РАБДОМИОЛИЗ,НАСЛЕДСТВЕННЫЙ РАБДОМИОЛИЗ,ОКРУЖАЮЩАЯ СРЕДА,ТЕРМОЛАБИЛЬНОСТЬ,АЛЬДОЛАЗА А,МИОПАТИЯ,МИОГЛОБИНУРИЯ,ПРОВОСПАЛИТЕЛЬНЫЕ МЕДИАТОРЫ,ГЕМОЛИТИЧЕСКАЯ АНЕМИЯ,МИОЗИТ,АДЕНОЗИНТРИФОСФАТ,СТАТИНЫ,ЛИПИДНЫЕ КАПЛИ,ДЕФЕКТ ß ОКИСЛЕНИЯ ЖИРНЫХ КИСЛОТ,ВРОЖДЕННЫЙ ДЕФЕКТ ГЛИКОГЕНОЛИЗА/ГЛИКОЛИЗА,МУТАЦИИ LPIN1,ДЕФЕКТ AMACR

وصف الملف: text/html

الاتاحة: http://cyberleninka.ru/article/n/ostryy-rabdomioliz
http://cyberleninka.ru/article_covers/15823696.png